Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
about
The therapeutic role of niacin in dyslipidemia managementEstimation of risk factor associations when the response is influenced by medication use: an imputation approach.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Utilization patterns of extended-release niacin in Canada: analysis of an administrative claims database.Niacin for primary and secondary prevention of cardiovascular events.Management of dyslipidemia in women in the post-hormone therapy era.Modification of high-density lipoprotein cholesterol in the management of cardiovascular risk.Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.Evidence-based and heuristic approaches for customization of care in cardiometabolic syndrome after spinal cord injury.Niaspan treatment improves neurological functional recovery in experimental autoimmune encephalomyelitis miceImportant considerations for treatment with dietary supplement versus prescription niacin products.Nicotinic acid and nicotinamide: a review of their use for hyperphosphatemia in dialysis patients.Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease.Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics.ARBITER 6-HALTS. Does it have the power to settle all matters?Niacin (nicotinic acid) in non-physiological doses causes hyperhomocysteineaemia in Sprague-Dawley rats.The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats.Natural approaches in metabolic syndrome management.The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats.Niacin-Induced Anicteric Microvesicular Steatotic Acute Liver Failure
P2860
Q28304559-A698F009-62B5-42BC-ABE6-3CC79720B89BQ33690940-BDA4E83A-CCAE-46A0-A76F-3975746677E2Q33765072-11AB97F2-A804-4381-B7FA-AD667F9C56E8Q34179056-6DCB034E-4846-4C3D-AB09-EB21F269C546Q34682221-D7ECE283-1A15-47B4-9F2B-86A7E0415B2CQ34722828-10DC2276-7B07-4A6E-9DC6-DC4B098B899DQ34975672-9C23EDA2-9F5E-4F55-8A14-1FFE7CDBF985Q35035100-DCAD3EC9-5DB2-4A18-9E55-9476D7EA2CFEQ36283606-8A28CB94-2CCA-4F33-B5EF-791B782947D3Q36995535-1AF0F128-20A3-46B6-9292-63DAC6272654Q37862929-1A4AB428-8CDF-4B8B-9C33-80DDB47CC47BQ38092792-C6AD0921-B878-4E18-B7D1-DCF1EDD24C70Q38217797-C876C03E-C77E-475B-B8B0-9CF51ECD25F4Q38727796-9FC88557-AD81-47E9-8C0A-4312FDC4D3E7Q40365888-FDD630A8-9FEC-4237-B1E4-13D4623751F5Q43111638-A9E2D4BE-A00F-4A7F-AD3A-C4E216430656Q43918127-A44F3783-B447-427C-A1B9-3B83AF668A89Q44652704-4E497050-0319-42A7-8B8D-0D4F25E114EFQ51526676-59292730-3693-49B2-896A-3533DA105D06Q51758644-12ABDDED-9D12-4B42-98D9-FA37C98D1D0CQ51789318-7A82A9D3-1F59-4F99-9E73-98A6F859B2C4Q58551494-A80F8E5A-B526-4FC6-8435-7CCBE2079B38
P2860
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
@en
Clinical trial experience with extended-release niacin
@nl
type
label
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
@en
Clinical trial experience with extended-release niacin
@nl
prefLabel
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
@en
Clinical trial experience with extended-release niacin
@nl
P1476
Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study.
@en
P2093
A C Goldberg
P304
35U-38U; discussion 39U-41U
P356
10.1016/S0002-9149(98)00952-7
P407
P577
1998-12-01T00:00:00Z